- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00608244
Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients
A Phase II, Open-Label, Multi-Center Prospective, Conversion Study in Stable Liver Transplant Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf® Capsules Twice-A-Day
Study Overview
Detailed Description
A three sequence, open-label, multi-center, prospective, study in stable liver transplant patients to assess and compare the pharmacokinetics (Cmax, C24, and AUC), and safety of LCP-Tacro (tacrolimus) tablets versus Prograf (tacrolimus) capsules.
Stable liver transplant patients who fulfill all I/E criteria will be enrolled and kept on Prograf for 7 days. Following a 24-hour PK study on Day 7 to determine pharmacokinetics for Prograf, all patients will be converted to once daily LCP-Tacro for 14 days with one fixed dose change allowed at Day 15.
On Day 14 and Day 21 a 24-hour LCP-Tacro PK study will be performed. On Day 22 patients will be converted back to their original twice daily dose of Prograf for a safety follow-up period of 30 days ending with a safety assessment on day 53.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 44123
- University of Cincinnati
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women 18-65 years of age who are recipients of a liver transplant at least six months prior to enrollment
- Patients on oral Prograf therapy as part of their maintenance immunosuppression therapy, with stable doses and trough levels of tacrolimus of 5-12 ng/mL for at least four weeks prior to enrollment with at least two measurements at least two days apart in the screening period up to fourteen days prior to enrollment
- Concurrent immunosuppression with mycophenolate mofetil (MMF, CellCept) or mycophenolic acid delayed-release tablets (Myfortic) is allowed but patients on either of these medications should be on stable doses for at least four weeks prior to enrollment
- Patients with stable serum bilirubin, AST, ALT, and Alk Phos or GGT that are ≤ 2 times the upper limit of normal based on local laboratory criteria
- Patients with serum creatinine ≤2.0 mg/dL prior to enrollment
- Able to swallow study medication
- Patients capable of understanding the purposes and risks of the study, who can give written informed consent and who are willing to participate in and comply with the study protocol.
- Women of childbearing potential must have a negative serum pregnancy test within seven days prior to receiving study medication and agree to use contraceptive measures to avoid pregnancy during participation in the trial.
Exclusion Criteria:
- Recipients of any transplanted organ other than a liver
- White blood cell count ≤ 2.8 x 109/L
- Patients who are receiving a total dose of Prograf < 3 mg per 24 hours
- Patients who are receiving more than 10 mg of prednisone per day
- Patients unable or unwilling to provide informed consent
- Pregnant or nursing women
- Patients with reproductive potential who are unwilling/unable to use a double barrier method of contraception
- Administration of any other investigational agent in the three months prior to enrollment
- Patients receiving any drug interfering with tacrolimus metabolism
- Patients who have taken sirolimus within the three months prior to screening
- Patient with an episode of acute cellular requiring antibody therapy within the six months prior to enrollment
- Patients treated for acute cellular rejection within the thirty days prior to enrollment
- Patient who is HCV negative and has received an HCV positive (HCV RNA by PCR or HCV antibody) donor liver
- Patients presenting after liver transplantation with recurrent HCV infection, documented by presence of HCV RNA in serum and grade II or greater inflammation or stage II or greater fibrosis on liver biopsy
- Patients being actively treated with antiviral therapy, such as interferons or ribavirin, for recurrent hepatitis C.
- Patients with an alpha-feto protein ≥ 20 ng/mL
- Patient has a current malignancy or a history of malignancy (within the past five years), except basal or non-metastatic squamous cell carcinoma of the skin that has been treated successfully
- Patient has uncontrolled concomitant infection, a systemic infection requiring treatment, or any other unstable medical condition that could interfere with the study objectives
- Patient has severe diarrhea, vomiting, active peptic ulcer or gastrointestinal disorder that may affect the absorption of tacrolimus
- Patient will require therapy with any immunosuppressive agent other than those prescribed in the study
- Patient has a known hypersensitivity to corticosteroids or tacrolimus
- Patient has any form of current substance abuse (patients must pass a standard drug screen), psychiatric disorder or a condition that, in the opinion of the Investigator, may invalidate communication with the Investigator Version
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: LCP-Tacro
Prograf was administrated BID, doses per product labeling, with an interval of 12±1 hours between the morning and evening doses. Patients continued on the same dose from Day 0 through Day 7. On Day 8, all patients were converted to LCP Tacro QD for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro was administered orally once daily in the morning, with an interval of 24 ± 1 h between doses. Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL. LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets. |
In the morning of Day 8 (after completing one week treatment with Prograf), all patients will be converted to LCP Tacro QD with a conversion ratio of 0.66-0.8. LCP-Tacro will be administered for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro will be administered orally once daily in the morning, with an interval of 24 ± 1 h between doses. Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL.
Other Names:
Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses.
Patients will continue on the same dose on Day 0 through Day 7 to maintain target trough levels of 5-12 ng/mL.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety Evaluation
Time Frame: 52 days
|
A combination of deaths, graft failure and biopsy proven acute rejections (BPAR) was used to evaluate the safety.
|
52 days
|
Evaluation of Steady State Tacrolimus Trough Levels (C24).
Time Frame: 7 Days
|
Patients had a baseline trough level (C24) measured at day 7 before conversion to LCP-Tacro.
|
7 Days
|
Evaluation of Steady State Tacrolimus Exposure (AUC 0-24).
Time Frame: 7 Days
|
Patients had a baseline AUC measured (0 to 24 hours) at day 7 before conversion to LCP-Tacro. The following time points were used to obtain the PK curve for Prograf on day 7: 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 15, 16, 20 and 24 hours after the morning dose. |
7 Days
|
Evaluation of Steady State Tacrolimus Exposure Trough Levels (C24).
Time Frame: 21 Days
|
Patients were converted from Prograf to LCP-Tacro on day 7. On day 21, a trough level (C24) was measured.
|
21 Days
|
Evaluation of Steady State Tacrolimus Exposure (AUC 0-24) on Day 21.
Time Frame: 21 Days
|
Patients were converted from Prograf to LCP-Tacro on day 7. On day 21, AUC was measured (0 to 24 hours). The following time points were used to obtain the PK curve for LCP-Tacro on day 21: 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 20 and 24 hours post-dose. |
21 Days
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LCP Tacro 2012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Failure
-
Institute of Liver and Biliary Sciences, IndiaCompletedAcute Liver FailureIndia
-
Beijing Continent Pharmaceutical Co, Ltd.RecruitingAcute-On-Chronic Liver Failure | Acute Liver FailureChina
-
HLB Cell Co., Ltd.UnknownAcute-On-Chronic Liver Failure | Acute Liver FailureKorea, Republic of
-
Tianjin Weikai Bioeng., Ltd.Tianjin Nankai HospitalUnknownLiver Failure, Acute on ChronicChina
-
Institute of Liver and Biliary Sciences, IndiaCompletedAcute Liver Failure | Acute on Chronic Liver FailureIndia
-
Nanfang Hospital of Southern Medical UniversityCompletedLiver Injury | Liver Failure, Acute on Chronic
-
Third Affiliated Hospital, Sun Yat-Sen UniversityWithdrawnLiver Failure, Acute on ChronicChina
-
Third Affiliated Hospital, Sun Yat-Sen UniversityWithdrawnAcute-On-Chronic Liver Failure | Acute Liver FailureChina
-
RenJi HospitalNot yet recruiting
-
RenJi HospitalShanghai Institute of Biochemistry and Cell BiologyNot yet recruitingAcute-On-Chronic Liver Failure | Chronic Liver Failure
Clinical Trials on LCP Tacro
-
Veloxis PharmaceuticalsCTI Clinical Trial and Consulting Services; AptuitCompletedRenal Failure | Kidney FailureUnited States
-
Veloxis PharmaceuticalsCompletedRenal Failure | TremorsUnited States
-
Regional Palliative Care NetworkCompleted
-
Lorenzo GallonCompletedEnd Stage Renal Disease | Rejection of Renal TransplantUnited States
-
Veloxis PharmaceuticalsCompleted
-
Veloxis PharmaceuticalsCompletedRenal FailureUnited States
-
University Hospital, AkerUniversity of OsloCompletedProximal Humeral Fracture | Osteosynthesis or Conservative TreatmentNorway
-
Veloxis PharmaceuticalsCTI Clinical Trial and Consulting ServicesCompleted
-
Veloxis PharmaceuticalsCTI Clinical Trial and Consulting Services; AptuitCompletedLiver FailureUnited States
-
Veloxis PharmaceuticalsPPDCompleted